AUGMENT-102: A Phase 1, Open-label, Dose-escalation Study to Evaluate Safety, Tolerability and Preliminary Anti-Leukemic Activity of SNDX-5613 in Combination with Chemotherapy in Patients with Relapsed/ Refractory Leukemias Harboring a KMT2A/MLL Gene Rearrangement or Nucleophosmin 1 Mutation mNPM1
A phase I/II trial of Rucaparib in combination with Ramucirumab with or without Nivolumab in previously treated patients with advanced gastric and esophageal adenocarcinoma RiME
NCI-COG Pediatric Match Molecular Analysis for Therapy Choice- Phase II Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations
A Window of Opportunity Study to Characterize the Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics of CPX-POM in Patients with Newly Diagnosed or Recurrent Bladder Tumors
A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation
Ice Compress: Randomized Trial of Limb Cryocompression versus continuous Compression versus Low Cyclic Compression for the Prevention of Taxane-Induced Peripheral Neuropathy
Phase 3 Study PACIFICA:
A Randomized, Controlled Phase 3 Study of Pacritinib versus Physician?s Choice in Patients with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia Platelet Counts < 50,000/�L